Photo by nci from unsplash
Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD‐L1) is a dominant mediator of immunosuppression, binding to programmed… Click to show full abstract
Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD‐L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD‐1). PD‐L1 is up‐regulated in cancer cells, and the PD‐1/PD‐L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD‐L1 expression and prognosis has been reported. Studies performed on histological material have revealed expression of PD‐L1 in MM, but no study has been performed on MM effusions thus far.
Journal Title: Cancer Cytopathology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!